Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director · President and CEO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,120,384 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Gift · Disposed 32,220 · Balance 2,120,384 F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund. F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | Direct | 296,833 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 296,833 F3: Includes 184,915 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an in-kind charitable contribution of 32,220 shares of DNLI to a donor advised fund.
F2: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F3: Includes 184,915 unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · derivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F7 · derivative.exercise_date: 50% of the restricted stock units vested on February 8, 2020 and the remaining 50% of the restricted stock units vested on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F7 · derivative.expiration_date: 50% of the restricted stock units vested on February 8, 2020 and the remaining 50% of the restricted stock units vested on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,318,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:40 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009455 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,310,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 02:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 560 | $69.69 | $39,026.40 |
DisclosureSEC source: 0001209191-21-007027 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,304,649 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 02:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,552 | $69.17 | $245,681.18 |
DisclosureSEC source: 0001209191-21-007027 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,305,209 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.64 to $69.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 02:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,222 | $68.21 | $970,111.06 |
DisclosureSEC source: 0001209191-21-007027 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,308,761 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.63 to $68.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · derivative · entry 20 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2031-01-03 F23 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · derivative · entry 19 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F21 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F22 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F22 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,142 | $84.24 | $96,204.48 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 18 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,322,978 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F20 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $84.16 to $84.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,225 | $83.43 | $102,198.20 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 17 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,324,120 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F19 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $83.07 to $84.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,410 | $82.44 | $610,875.21 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 16 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,325,345 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F18 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $82.03 to $83.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,539 | $81.66 | $615,630.97 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 15 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,332,755 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F17 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $81.03 to $82.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,400 | $80.25 | $112,343.98 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 14 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,340,294 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F16 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $79.99 to $80.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,208 | $79.57 | $334,837.71 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 13 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,341,694 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $78.94 to $79.91 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,482 | $78.41 | $743,502.58 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 12 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,345,902 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $77.94 to $78.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,740 | $77.29 | $134,480.42 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 11 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,355,384 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $76.93 to $77.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,620 | $76.07 | $123,236.32 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 10 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,357,124 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.56 to $76.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,100 | $74.52 | $81,968.04 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 9 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,358,744 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.36 to $75.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 7,322 | $73.78 | $540,188.60 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 8 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,359,844 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.30 to $74.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,443 | $72.63 | $685,851.70 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 7 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,367,166 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.30 to $73.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,683 | $71.77 | $623,217.98 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,376,609 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.30 to $72.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 11,896 | $70.82 | $842,479.48 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,385,292 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.29 to $71.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 9,900 | $70.02 | $693,181.17 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,397,188 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.29 to $70.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,224 | $68.26 | $83,551.71 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,407,088 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.80 to $68.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,700 | $66.63 | $113,265.05 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,408,312 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.32 to $67.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:49 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,300 | $65.21 | $84,768.06 |
DisclosureSEC source: 0001209191-21-002342 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,410,012 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.95 to $65.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047792 · doc4.xml · derivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 01:42 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037765 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,389,304 F1 · kind: The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:17 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,807 | $19.48 | $93,640.36 |
DisclosureSEC source: 0001209191-20-022238 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,013 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.45 to $19.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 367,675 | $0.00 Strike: $24.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008923 · doc4.xml · derivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,675 Underlying: Common Stock · 367,675 shares Expires 2030-02-09 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 10, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 78,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008923 · doc4.xml · derivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,787 Underlying: Common Stock · 78,787 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2020 Filed Apr 1, 2020 22:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022234 · doc4a.xml · derivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 8,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 25% of the restricted stock units vested on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F3 · derivative.expiration_date: 25% of the restricted stock units vested on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2020 Filed Apr 1, 2020 22:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022234 · doc4a.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,516 Underlying: Common Stock · 5,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 50% of the restricted stock units vested on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 50% of the restricted stock units vested on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2020 Filed Apr 1, 2020 22:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 8,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-022234 · doc4a.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 08, 2020 Filed Apr 1, 2020 22:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-022234 · doc4a.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,755 | $18.00 | $337,590.00 |
DisclosureSEC source: 0001209191-19-059302 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,429,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,513 | $18.02 | $45,284.26 |
DisclosureSEC source: 0001209191-19-059302 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,448,059 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 23:17 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 42,185 | $18.02 | $760,173.70 |
DisclosureSEC source: 0001209191-19-058172 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,450,572 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.12 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 23:17 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,300 | $18.00 | $23,400.00 |
DisclosureSEC source: 0001209191-19-058172 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,492,757 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| September 05, 2019 Filed Sep 5, 2019 22:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 4,847 | $18.09 | $87,682.23 |
DisclosureSEC source: 0001209191-19-048640 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,494,057 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 22:51 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,734 | $18.00 | $67,212.00 |
DisclosureSEC source: 0001209191-19-048640 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,498,904 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,333 | $20.76 | $380,593.08 |
DisclosureSEC source: 0001209191-19-041176 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,502,638 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.60 to $21.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 21:15 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,333 | $19.07 | $349,610.31 |
DisclosureSEC source: 0001209191-19-034830 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,560,971 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.87 to $19.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 14, 2019 Filed Jul 3, 2019 20:47 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041176 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,520,971 F1 · kind: The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. F2 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 03, 2019 Filed May 3, 2019 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,111 | $24.49 | $149,658.39 |
DisclosureSEC source: 0001209191-19-027547 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,579,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.12 to $24.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 02, 2019 Filed May 3, 2019 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,111 | $24.03 | $146,847.33 |
DisclosureSEC source: 0001209191-19-027547 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,585,415 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.69 to $24.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| May 01, 2019 Filed May 3, 2019 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,112 | $24.09 | $147,238.08 |
DisclosureSEC source: 0001209191-19-027547 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,591,526 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.76 to $24.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 03, 2019 Filed Apr 3, 2019 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 500 | $26.77 | $13,385.00 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,597,638 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $26.75 to $26.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 03, 2019 Filed Apr 3, 2019 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,641 | $26.28 | $148,245.48 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,598,138 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.73 to $26.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 23:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,942 | $25.17 | $74,050.14 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,603,779 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.87 to $25.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.